Sci Show: Published trial results show that the monoclonal antibodies gantenerumab and solanezumab were unable to improve cognition in patients with dominantly inherited Alzheimer’s disease, despite improving molecular biomarkers of the disease.

Monday, June 21, 2021

Published trial results show that the monoclonal antibodies gantenerumab and solanezumab were unable to improve cognition in patients with dominantly inherited Alzheimer’s disease, despite improving molecular biomarkers of the disease.

https://ift.tt/3xGK4Xw via /r/science https://ift.tt/3qeYoEd

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)